The International Vaccine Institute (IVI) has been honored with the Presidential Citation of the Republic of Korea’s Development Cooperation Award, in recognition of IVI’s contributions to global health and Korea’s official development assistance.
IVI has been cited as being an “International organization focused on global health and health ODA, including the development and technology transfer of the world’s first low-cost oral cholera vaccine, which carries out impactful ODA projects in collaboration with governments around the world as well as the Government of Korea.” It is the first time that IVI has received such an award from its host country and state funder since the institute’s establishment in 1997.
Dr. Jerome Kim, Director General of IVI, received the prize from Prime Minister Kim Bu-gyeom at an award ceremony commemorating Development Cooperation Day in Korea on November 25 (the day when Korea joined OECD’s Development Assistance Committee in 2009).
“This honor represents ROK’s recognition of IVI’s growing contributions to global health, the demonstrated impact of Korean ODA through IVI, and the dedication and hard work of our staff,” Dr. Kim said. “With support from ROK and other state funders, IVI will continue to discover, develop, and deliver safe, effective, and affordable vaccines and increase impact in global health in collaboration with our partners and stakeholders worldwide.”
About the International Vaccine Institute (IVI)
The International Vaccine Institute (IVI) is a nonprofit inter-governmental organization established in 1997 at the initiative of the United Nations Development Programme (UNDP). IVI has 36 countries and the World Health Organization (WHO) on its treaty, including the Republic of Korea, Sweden, India, and Finland as state funders.
Our mandate is to make vaccines available and accessible for the world’s most vulnerable people. We focus on infectious diseases of global health importance such as cholera, typhoid, shigella, salmonella, schistosomiasis, chikungunya, group A strep, Hepatitis A, HPV, TB, HIV, MERS, COVID-19, as well as antimicrobial resistance. For more information, please visit https://www.ivi.int.